THERAVECTYS is a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology.

TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs.

THERAVECTYS was founded in 2005 by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute. The company is based in Paris, Ile-de-France, France.


TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market.


TheraVectys is backed by investors including Bpifrance, Tethys BioScience, & Richard HENNESSY among others.




  • Year founded: 2005
  • Funding Info: €24.1M in 3 funding rounds (Last funding type: Grant)
  • Yearly Revenue: $2M-$5M (2018)
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Paris
  • State: Ile-de-France
  • Country: France
Related businesses